Dermata (NASDAQ: DRMA) awards 18,000 stock options to Senior VP Nardo

Rhea-AI Filing Summary

Dermata Therapeutics executive Christopher J. Nardo, Senior VP and Chief Development Officer, reported a new equity award in the form of stock options. On January 2, 2026, he was granted an option to purchase 18,000 shares of Dermata Therapeutics common stock at an exercise price of $2.18 per share. The filing states that 25% of the shares underlying the option will vest on the 12‑month anniversary of the grant date, with the remaining 75% vesting in 36 equal monthly installments starting on that same 12‑month anniversary. Following this grant, he beneficially owns stock options for 18,000 shares, held as direct ownership.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nardo Christopher J.

(Last) (First) (Middle)

3525 DEL MAR HEIGHTS RD., #322

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Dermata Therapeutics, Inc. [ DRMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Senior VP, CDO

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.18	01/02/2026		A		18,000		(1)	01/01/2036	Common Stock	18,000	$0	18,000	D

Explanation of Responses:

1. The shares underlying the option will vest as to 25% upon the 12 month anniversary of the grant date, and will vest as to 75% in 36 equal monthly installments commencing on the 12 month anniversary of the grant date.

	/s/ Gerald T. Proehl, Attorney-in-Fact	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Dermata Therapeutics (DRMA) report for Christopher J. Nardo?

The company reported that Senior VP and Chief Development Officer Christopher J. Nardo received a grant of stock options for 18,000 shares of Dermata Therapeutics common stock on January 2, 2026.

What is the exercise price of the new Dermata Therapeutics (DRMA) stock options?

The reported stock option grant to Christopher J. Nardo has an exercise price of $2.18 per share for 18,000 shares of Dermata Therapeutics common stock.

How do the Dermata Therapeutics (DRMA) options granted to Christopher J. Nardo vest?

According to the filing, 25% of the option shares will vest on the 12‑month anniversary of the grant date, and the remaining 75% will vest in 36 equal monthly installments beginning on that 12‑month anniversary.

How many Dermata Therapeutics (DRMA) derivative securities does Christopher J. Nardo own after this transaction?

After the reported grant, Christopher J. Nardo beneficially owns 18,000 stock options related to Dermata Therapeutics common stock, reported as direct ownership.

What role does Christopher J. Nardo hold at Dermata Therapeutics (DRMA)?

The reporting person for this insider transaction is Christopher J. Nardo, who serves as Senior Vice President and Chief Development Officer of Dermata Therapeutics.

Was the reported Dermata Therapeutics (DRMA) transaction a purchase, sale, or grant of options?

The transaction reported was a grant of stock options (transaction code A) for 18,000 derivative securities rather than an open‑market purchase or sale of common shares.